Uncategorized

Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.

Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024 Read More »

Epredia and NovaScan Announce Intent to Enter U.S. Distribution Agreement for MarginScan™ Device for Non-Melanoma Skin Cancer Detection

Epredia and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScan™, a medical device that will support physicians in real-time detection of non-melanoma skin cancer.

Epredia and NovaScan Announce Intent to Enter U.S. Distribution Agreement for MarginScan™ Device for Non-Melanoma Skin Cancer Detection Read More »

Scroll to Top